SCHEMBL24936302

SCHEMBL24936302

COc1ccnc(O)c1-c1ccno1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 3/20 0.36
CYP19A1 P11511 3/20 0.36
CYP2C9 P11712 3/20 0.36
CYP2C19 P33261 3/20 0.36
CYP2D6 P10635 1/20 0.36
EPHX2 P34913 1/20 0.34
ILK Q13418 1/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
NOTUM Q6P988 1/20 0.33
MAPT P10636 4/20 0.31
TP53 P04637 2/20 0.31
PLAU P00749 1/20 0.31
HIF1A Q16665 1/20 0.31
EPAS1 Q99814 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29632578 1.00 KDM4E (0.36) KDM4EALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL29788605 0.77 MEN1 (0.47) KDM4EALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL28548601 0.77 MEN1 (0.47) KDM4EALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL24936306 0.71 MAPT (0.35) CYP1A2CYP19A1CYP2C9CYP2C19MAPT
SCHEMBL29045194 0.70 CYP1A2 (0.35) KDM4EGAASMN1; SMN2CYP1A2CYP19A1
SCHEMBL29632631 0.67 CYP1A2 (0.52) KDM4EALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL23084830 0.67 KDM4E (0.45) KDM4EALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL8244559 0.66 IKBKB (0.44) KDM4EALDH1A1GAAMAPK1MAPT
SCHEMBL18955276 0.66 CYP1A2 (0.43) KDM4EALDH1A1GAACYP1A2CYP19A1
SCHEMBL2093729 0.66 CYP1A2 (0.62) KDM4EALDH1A1GAASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022109-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2026-01-22 US disclosed
US-20250352541-A1 THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR Sumitomo Pharma Co., Ltd. (JP) 2025-11-20 US disclosed
US-12410154-B2 5-heteroaryl-1H-pyrazol-3-amine derivative Sumitomo Pharma Co., Ltd. (JP) 2025-09-09 US disclosed
EP-4534100-A1 THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR Sumitomo Pharma Co., Ltd. (JP) 2025-04-09 EP disclosed
WO-2023229032-A1 THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR 住友ファーマ株式会社 2023-11-30 WO disclosed
EP-4253377-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-10-04 EP disclosed
CN-116546974-A 5-heteroaryl-1H-pyrazol-3-amine derivatives 住友制药株式会社 2023-08-04 CN disclosed
US-11564920-B2 5-heteroaryl-1H-pyrazol-3-amine derivative Sumitomo Pharma Co., Ltd. (JP) 2023-01-31 US disclosed
US-11564920-B2 5-heteroaryl-1H-pyrazol-3-amine derivative Sumitomo Pharma Co., Ltd. (JP) 2023-01-31 US disclosed
US-20230025065-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-01-26 US disclosed
US-20230025065-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-01-26 US disclosed
US-20220273649-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2022-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11564920-B2 5-heteroaryl-1H-pyrazol-3-amine derivative CHEK1, CHEK2, RB1 KDM4E 866/4885ALDH1A1 3927/4885GAA 2984/4885
US-20230025065-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE CHEK1, CHEK2, RB1 KDM4E 866/4885ALDH1A1 3927/4885GAA 2984/4885
US-20260022109-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE CHEK1, CHEK2, WEE1 KDM4E 841/4885ALDH1A1 3317/4885GAA 3699/4885
US-20220273649-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE CHEK1, CHEK2, RB1 KDM4E 866/4885ALDH1A1 3927/4885GAA 2984/4885
US-12410154-B2 5-heteroaryl-1H-pyrazol-3-amine derivative CHEK1, CHEK2, RB1 KDM4E 866/4885ALDH1A1 3927/4885GAA 2984/4885
US-20250352541-A1 THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR CHEK1, CHEK2, PDCD1 KDM4E 449/4885ALDH1A1 3803/4885GAA 3303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.